Clovis Oncology Inc. (CLVS)

24.84
NASDAQ : Health Technology
Prev Close 26.13
Day Low/High 24.80 / 26.33
52 Wk Low/High 11.50 / 65.24
Avg Volume 1.98M
Exchange NASDAQ
Shares Outstanding 52.87M
Market Cap 1.38B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

ARIEL3 Trial Fact Sheet

ARIEL3 Trial Fact Sheet

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca ® (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian...

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

Clovis Oncology Announces 2018 Operating Results

Clovis Oncology Announces 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2019.

Clovis Oncology To Present At The 8th Annual SVB Leerink Healthcare Conference

Clovis Oncology To Present At The 8th Annual SVB Leerink Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models --

Clovis Oncology To Announce Fourth Quarter/Fiscal Year 2018 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology To Announce Fourth Quarter/Fiscal Year 2018 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.

Clovis Oncology Announces European Commission Authorization Of Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology Announces European Commission Authorization Of Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has approved the use of Rubraca ® (rucaparib) for a second indication, as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed...

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Clovis Oncology Announces Product Revenues For The Fourth Quarter And Full Year 2018

Clovis Oncology Announces Product Revenues For The Fourth Quarter And Full Year 2018

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018.

First Week Of CLVS February 15th Options Trading

First Week Of CLVS February 15th Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include...

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate,...

First Week Of CLVS July 2019 Options Trading

First Week Of CLVS July 2019 Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations.

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the remainder of 2018.

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology).

How Clovis Calls Prices Increased Overnight

How Clovis Calls Prices Increased Overnight

Trying to find a bottom in share price can be difficult, but these investors may have wanted to wager a retrace was do with an equivalent 2.18% 'stop-loss' should their idea take longer to play out.

Clovis Oncology To Announce Third Quarter 2018 Financial Results And Host Webcast Conference Call On October 30

Clovis Oncology To Announce Third Quarter 2018 Financial Results And Host Webcast Conference Call On October 30

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2018 financial results on Tuesday, October 30, 2018, after the close of the U.

Clovis Oncology Appoints Two New Directors To Its Board

Clovis Oncology Appoints Two New Directors To Its Board

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today the appointment of Robert W.

2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs

2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs

This is why I always have some 'dry powder' to deploy during these temporary hiccups.

Clovis Oncology To Highlight Results From Rubraca® (rucaparib) TRITON Prostate Program At ESMO 2018 Congress

Clovis Oncology To Highlight Results From Rubraca® (rucaparib) TRITON Prostate Program At ESMO 2018 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four posters featuring data and highlighting studies from the Rubraca clinical development program will be presented at the ESMO 2018 Congress (European Society for Medical Oncology), 19-23...

Interesting CLVS Put And Call Options For January 2021

Interesting CLVS Put And Call Options For January 2021

Investors in Clovis Oncology Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

TheStreet Quant Rating: D- (Sell)